Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health
Genexis Health
Compounds
Metabolic

AOD-9604

Also known as hGH fragment 176-191 · developed by Metabolic Pharmaceuticals

Tested in humans, did not show benefit

Taken into human trials and did not outperform placebo on its primary endpoint, or development was discontinued. This is stronger evidence than "untested" — it is evidence of absence, not absence of evidence.

Not approved anywhere No regulator has licensed this compound for any indication. It has no established safe dose in humans.
Illustration only. Not a photograph of a product, and not an offer of supply — Genexis Health does not sell or supply AOD-9604.

What it is

A fragment of the C-terminus of human growth hormone, developed specifically as a weight-loss drug on the theory that the fat-metabolising properties of growth hormone could be separated from its growth effects.

How it is thought to work

Proposed to stimulate lipolysis and inhibit lipogenesis without the IGF-1 mediated effects of full-length growth hormone.

What the studies found

  • Human trials did not show weight loss

    A 12-week randomised placebo-controlled trial in obese participants found no significant difference in weight loss versus placebo. Development for obesity was discontinued.

  • Encouraging animal data that did not replicate

    Rodent studies had shown reductions in body fat. This is a clear worked example of animal results failing to carry over to humans.

What the evidence does not show

  • This is a compound with a negative human result, not an untested one. The trial was done and it did not work for its intended purpose.
  • Later interest concerned cartilage and osteoarthritis rather than fat loss, and did not reach approval either.

Reported risks and adverse effects

  • Short-term tolerability in the obesity trials appeared acceptable — the problem was efficacy, not safety.
  • No long-term safety data.
  • Prohibited by WADA.

This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.

Regulatory status

Not approved as a medicine anywhere. Marketed in some places as a supplement ingredient, which regulators including the FDA have challenged.

Related

More in Metabolic & incretin

Semaglutide

Approved

A long-acting analogue of GLP-1, a hormone the gut releases after eating. Structural changes — an Aib substitution that …

Tirzepatide

Approved

A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions tha…

Retatrutide

Phase 3

An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it…